Sign up USA
Proactive Investors - Run By Investors For Investors

Soligenix shares skyrocket on RiVax development program news

Ricin is an extremely dangerous poison, which has been used as a weapon and by terrorists.
Soligenix shares skyrocket on RiVax development program news
Ricin has been used as a biological weapon

Soligenix Inc (NASDAQ:SNGX) shares surged over 52% in New York as it posted positive data on its ricin toxin vaccine called RiVax.

Ricin is an extremely dangerous poison, which has been used as a  weapon and by terrorists.

It  can be inhaled, injected, ingested, or absorbed through eyes or damaged skin.

A vaccine against it is hoped to deter its use as a biological weapon.

The firm has shown RiVax has enhanced thermostability and 100% protection in pre-clinical ricin aerosol challenge models and will be showcasing results from the candidate's development program at a conference in Bethesda, Maryland  from April 24  to 26.

It is hoped the findings will aid approval of RiVax by the US Food and Drug Administration (FDA).

Shares added 52.87% to $3.93.

Giles_55af4ddca6481.jpg


Register here to be notified of future SNGX Company articles
View full SNGX profile View Profile

Soligenix Timeline

Related Articles

GW_Pharma.png
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
picture of drug lab
February 07 2017
Amryt Pharma’s strategy to acquire, in-license and then develop drugs for hard to treat, so-called orphan diseases has been seeing some good progress.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use